Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTXNASDAQ:FLKSNASDAQ:MRSNNASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$4.88$4.48$3.39▼$16.00$52.79M0.758,792 shs20,172 shsFLKSFlex Pharma$0.71-4.4%$6.86$0.26▼$1.49$12.78M1.652.03 million shs79,060 shsMRSNMersana Therapeutics$0.360.0%$0.35$0.26▼$2.83$45.24M0.834.41 million shs926,397 shsPEPGPepGen$1.41-4.4%$1.43$0.88▼$19.30$45.97M1.3828,762 shs33,329 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+3.61%+12.70%+32.61%-33.96%-57.53%FLKSFlex Pharma+0.46%-5.13%-6.65%-22.74%+65.06%MRSNMersana Therapeutics-4.55%-1.41%+1.37%-21.90%-84.04%PEPGPepGen+1.38%+3.52%-3.92%-38.49%-91.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics3.6067 of 5 stars3.55.00.00.02.81.71.3FLKSFlex PharmaN/AN/AN/AN/AN/AN/AN/AN/AMRSNMersana Therapeutics4.1293 of 5 stars3.54.00.04.11.62.50.0PEPGPepGen2.7389 of 5 stars3.23.00.00.01.72.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 3.00Buy$30.00514.75% UpsideFLKSFlex Pharma 0.00N/AN/AN/AMRSNMersana Therapeutics 3.00Buy$5.201,332.51% UpsidePEPGPepGen 2.33Hold$7.67445.67% UpsideCurrent Analyst Ratings BreakdownLatest FLKS, AVTX, MRSN, and PEPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025MRSNMersana TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform6/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.005/29/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $8.005/16/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.005/16/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/15/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$3.005/9/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $14.005/6/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00 ➝ $3.003/25/2025AVTXAvalo TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform ➝ Buy$23.003/25/2025AVTXAvalo TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.003/20/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$441K119.82N/AN/A$9.11 per share0.54FLKSFlex Pharma$840K15.21N/AN/A$0.51 per share1.39MRSNMersana Therapeutics$34.01M1.33N/AN/A$0.31 per share1.17PEPGPepGenN/AN/AN/AN/A$4.55 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$31.54MN/A0.00N/AN/AN/A-442.16%122.99%8/11/2025 (Estimated)FLKSFlex Pharma-$21.92MN/A0.00∞N/A-1,208.42%-98.04%-83.37%N/AMRSNMersana Therapeutics-$171.67M-$0.59N/AN/AN/A-214.20%-401.37%-38.61%8/12/2025 (Estimated)PEPGPepGen-$78.63M-$3.13N/AN/AN/AN/A-60.17%-48.88%8/6/2025 (Estimated)Latest FLKS, AVTX, MRSN, and PEPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MRSNMersana Therapeutics-$0.21-$0.19+$0.02-$0.19$6.05 million$2.75 million5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A5/8/2025Q1 2025PEPGPepGen-$0.72-$0.92-$0.20-$0.92N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AFLKSFlex PharmaN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A1.421.42FLKSFlex PharmaN/A6.866.74MRSNMersana Therapeutics13.352.352.35PEPGPepGenN/A8.478.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%FLKSFlex Pharma14.42%MRSNMersana Therapeutics93.92%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics3.03%FLKSFlex Pharma7.62%MRSNMersana Therapeutics13.00%PEPGPepGen5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4010.83 million10.37 millionNot OptionableFLKSFlex Pharma418.07 millionN/ANot OptionableMRSNMersana Therapeutics150124.63 million108.96 millionOptionablePEPGPepGen3032.72 million31.10 millionNot OptionableFLKS, AVTX, MRSN, and PEPG HeadlinesRecent News About These CompaniesLevi & Korsinsky Reminds PepGen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 8, 2025 – PEPGJune 13 at 1:31 PM | globenewswire.comLost Money on PepGen Inc. (PEPG)? Join Class Action Before August 8, 2025 - Contact Levi & KorsinskyJune 13 at 7:30 AM | accessnewswire.comPEPG INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PepGen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 13 at 7:00 AM | accessnewswire.comPepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPGJune 13 at 5:45 AM | prnewswire.comLost Money on PepGen Inc. (PEPG)? Join Class Action Before August 8, 2025 - Contact Levi & KorsinskyJune 12 at 6:30 PM | accessnewswire.comPEPG Investor Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against PepGen Inc.June 12 at 6:19 PM | prnewswire.comPEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 12 at 5:57 PM | prnewswire.comSecurities Lawsuit Alert: PepGen Inc. (PEPG) Investors - Contact Levi & Korsinsky Before August 8, 2025June 12 at 4:30 PM | accessnewswire.comSHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against PepGen Inc. (NASDAQ:PEPG)June 12 at 4:17 PM | accessnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPGJune 12 at 9:00 AM | prnewswire.comLevi & Korsinsky Urges PepGen Inc. (PEPG) Shareholders to Act Before Lead Plaintiff Deadline August 8, 2025June 12 at 7:30 AM | accessnewswire.comPEPG INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PepGen Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!June 12 at 7:00 AM | accessnewswire.comShareholders of PepGen Inc. Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights - PEPGJune 12 at 5:45 AM | prnewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds PepGen Inc. (PEPG) Investors of August 8, 2025 DeadlineJune 11 at 9:15 PM | accessnewswire.comPEPGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against PepGen, Inc. and Encourages Investors to Contact the FirmJune 11 at 9:00 PM | globenewswire.comLevi & Korsinsky Notifies PepGen Inc. (PEPG) Investors - Lead Plaintiff Deadline on August 8, 2025June 11 at 7:45 PM | accessnewswire.comROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPGJune 11 at 7:29 PM | globenewswire.comPepGen Faces Legal Storm Over Drug Trial DebacleJune 11 at 6:16 PM | msn.comInvestors in PepGen Inc. (PEPG): Protect Your Rights - Contact Levi & Korsinsky Before August 8, 2025June 11 at 4:30 PM | accessnewswire.comPepGen Inc. (PEPG) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 8, 2025June 11 at 4:00 PM | accessnewswire.comPepGen (NASDAQ:PEPG) Given New $8.00 Price Target at HC WainwrightMay 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLKS, AVTX, MRSN, and PEPG Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$4.88 0.00 (0.00%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Flex Pharma NASDAQ:FLKSFlex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.Mersana Therapeutics NASDAQ:MRSN$0.36 0.00 (-0.03%) As of 02:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.PepGen NASDAQ:PEPG$1.40 -0.07 (-4.42%) As of 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: Two Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
